Magnetic Resonance Imaging for the Detection of Nasopharyngeal Carcinoma

References

1. ↵
   Chong VF, Fan YF. Skull base erosion in nasopharyngeal carcinoma: detection by CT and MRI. Clin Radiol 1996;51:625–31

   CrossRefPubMedWeb of Science
2. Ng SH, Chang TC, Ko SF, et al. Nasopharyngeal carcinoma: MRI and CT assessment. Neuroradiology 1997;39:741–46

   CrossRefPubMedWeb of Science
3. Chong VF, Fan YF. Khoo JB. Computed tomographic and magnetic resonance imaging findings in paranasal sinus involvement in nasopharyngeal carcinoma. Ann Acad MedSingapore 1998;27:800–04
4. AD King, W Lam, SF Leung, et al. MR imaging of local disease in nasopharyngeal carcinoma: tumour extent vs tumour stage. BJR 1999;2:734–41
5. Poon PY, Tsang VH, Munk PL. Tumour extent and T stage of nasopharyngeal carcinoma: a comparison of magnetic resonance imaging and computed tomographic findings. Can Assoc Radiol J 2000;51:287–95

   PubMedWeb of Science
6. ↵
   King AD, Teo P, Lam WWM, et al. Staging of paranasopharyngeal tumor extension in nasopharyngeal carcinoma: MR Vs CT imaging. Clin Oncol 2000;12:397–402

   CrossRef
7. ↵
   Harnsberger HR. Squamous cell carcinoma: primary tumor staging and follow-up, in Handbook of Head and Neck Imaging. 2nd ed. St. Louis: Mosby;1995 :263–82
8. ↵
   Tsang RKY, Vlantis AC, Ho RWK, et al. Sensitivity and specificity of Epstein-barr virus IgA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck 2004;26:598–602

   CrossRefPubMed
9. ↵
   Leung SF, Tam JS, Chan ATC, et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 2004;50:339–45

   Abstract/FREE Full Text
10. ↵
    Cheng WM, Chan KH, Chen HL, et al. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antiobody spectrum. Int J Cancer 2002;97:489–92

    CrossRefPubMedWeb of Science
11. ↵
    Ng WT, Yau TK, Yung RWH, et al. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 2005;113:998–1001

    CrossRefPubMed
12. ↵
    Chan AKC, Lo DYM. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Cancer Biology 2002;12:489–96
13. ↵
    Shao JY, Li YH, Gao HY, et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 2004;100:1162–70

    CrossRefPubMed